174 related articles for article (PubMed ID: 36691306)
1. Integrating semaglutide into obesity management - a primary care perspective.
Kyrillos JV; Skolnik NS; Mukhopadhyay B; Pennings N
Postgrad Med; 2022 Jan; 134(sup1):37-49. PubMed ID: 36691306
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
Lau DCW; Batterham RL; le Roux CW
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Amaro A; Sugimoto D; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
[TBL] [Abstract][Full Text] [Related]
4. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
Kyrillos JV; O'Neil PM; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):1-4. PubMed ID: 36691310
[No Abstract] [Full Text] [Related]
5. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
6. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
7. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
8. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
9. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Kushner RF; Calanna S; Davies M; Dicker D; Garvey WT; Goldman B; Lingvay I; Thomsen M; Wadden TA; Wharton S; Wilding JPH; Rubino D
Obesity (Silver Spring); 2020 Jun; 28(6):1050-1061. PubMed ID: 32441473
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
13. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
14. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
15. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
16. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
18. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
19. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
20. Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
Kyrillos J
Am J Manag Care; 2022 Dec; 28(15 Suppl):S297-S306. PubMed ID: 36525677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]